A Clinical Trial to Compare the Efficacy of Tadalafil in Pulmonary Hypertension and Interstitial Lung Disease
| Author | Guitti Pourdowlat | en |
| Author | Bahador Bagheri | en |
| Author | Habib Emami | en |
| Author | Seyyed Reza Seyyedi | en |
| Author | Mahboubeh Darban | en |
| Orcid | Bahador Bagheri [0000-0003-2574-8034] | en |
| Issued Date | 2025-10-31 | en |
| Abstract | Background: To determine the effects of oral tadalafil on respiratory function in patients with interstitial lung disease (ILD), both with and without pulmonary hypertension (PH). Methods: Patients with ILD-PH (WHO classes 2 and 3) were assigned to group A, while patients with ILD without PH were assigned to group B. Participants in both groups received a daily dose of 40 mg oral tadalafil as an add-on therapy to their conventional treatments for a duration of 6 months. The study outcomes included changes in forced vital capacity (FVC), total lung capacity (TLC), diffusion lung capacity for carbon monoxide (DLCO), residual volume (RV), and a 6-minute walk distance (6MWD). Results: Of the 38 patients enrolled, 34 completed the 6-month treatment and were included in the final analysis. The mean age of participants was 50 years. At 6 months, no significant changes were observed in FVC, forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and DLCO. However, patients receiving tadalafil showed a significant improvement in median (interquartile range [IQR]) TLC after 6 months of treatment (77.1 [70.2-80.1] mL in group A versus 86.2 [86.3 - 93.1] mL in group B, P = 0.002) and in median (IQR) RV (83.1 [79.1 - 85.2] mL in group A versus 90.2 [86.3 - 93.1] mL in group B, P = 0.02). Additionally, no significant differences were noted in pulmonary arterial pressure (PAP) and 6MWD. No serious adverse effects were reported. Conclusions: A 6-month therapy with tadalafil was shown to partially improve respiratory function in patients with ILD, both with and without PH. This treatment demonstrated an acceptable safety profile. | en |
| DOI | https://doi.org/10.5812/mejrh-150893 | en |
| URI | https://brieflands.com/journals/mejrh/articles/150893 | en |
| Keyword | Tadalafil | en |
| Keyword | Pulmonary Hypertension | en |
| Keyword | Interstitial Lung Disease | en |
| Keyword | Systemic Sclerosis | en |
| Publisher | Brieflands | en |
| Title | A Clinical Trial to Compare the Efficacy of Tadalafil in Pulmonary Hypertension and Interstitial Lung Disease | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- mejrh-12-4-150893-publish-pdf.pdf
- Size:
- 243.82 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF